The pharmacokinetics of tacrolimus have been studied in healthy volunteers and in adults undergoing bone marrow transplantation. However, there is little information on the pharmacokinetics of tacrolimus in children undergoing BMT. We studied pharmacokinetics of tacrolimus in seven patients (age 8-17 years) undergoing allogeneic stem cell transplantation. Four patients received matched unrelated donor (MUD) transplants, two underwent HLA-matched related donor transplants, and one underwent an umbilical cord blood donor transplant. All patients received tacrolimus by continuous infusion at 0.03-0.04 mg/kg/day beginning on the day prior to transplant. Tacrolimus whole blood concentrations were monitored by microparticle enzyme immunoassay. Our goal was to maintain a blood tacrolimus level of 10-20 g/ml. Once patients were tolerating oral medications, tacrolimus infusion was converted to oral dosing using a 4:1 conversion. Dose of tacrolimus and resulting tacrolimus concentrations were recorded and the total body clearance of tacrolimus was calculated retrospectively. The mean clearance, based on first steady-state tacrolimus concentrations necessary for achieving a therapeutic level (10-20 g/ml), was 108.1 ml/h/kg (range 79.7-142.0 ml/h/kg), greater than that reported in adult BMT patients (71 ؎ 34 ml/h/kg). The average dose required to achieve that therapeutic range was 0.0354 mg/kg/day as an intravenous continuous infusion. Over the entire course of intravenous tacrolimus, mean clearance was 97.0 ml/h/kg (range 33.4-153.3 ml/h/kg). In six of the seven patients, clearance values dropped after 2-4 weeks of therapy by an average of 32.5 ml/h/kg. In two patients, sharp drops in clearance were temporally related to changes in liver function tests. Three of the seven patients died of severe acute GVHD; all these had undergone matched unrelated donor transplantation, and two of these three had initial clearance levels over 120 ml/h/kg. Thus, children appear to have more rapid tacrolimus clearance than adults and may need to begin therapy earlier in order to obtain stable and optimal 
levels. More studies are needed to confirm these preliminary results. Keywords: tacrolimus; pharmacokinetics; marrow transplantation; children Tacrolimus is widely used in solid organ transplantation to prevent graft rejection. [1] [2] [3] It has recently also been extensively used in bone marrow transplantation (BMT) to protect against graft-versus-host disease (GVHD). [4] [5] [6] Tacrolimus has replaced cyclosporine as the drug of choice for prophylaxis against GVHD in many transplant protocols, particularly those involving matched unrelated donors. It is a macrolide 2 that exerts its immunosuppressive activity by inhibiting the transcription of the genes that encode interleukin-2 in T cells and by inhibiting T cell growth and proliferation. 7 The pharmacokinetics of tacrolimus have been studied in healthy volunteers and in adults undergoing liver, renal and bone marrow transplantation. [8] [9] [10] Tacrolimus is incompletely and erratically absorbed from the gastrointestinal tract with only about 30% oral bioavailability. Administration of tacrolimus with a meal that is moderate in fat content may reduce the extent and rate of absorption of tacrolimus. Tacrolimus has a very large volume of distribution, undergoing extensive tissue distribution. The distribution of tacrolimus is primarily in whole blood with concentrations in whole blood 10 to 30 times higher than in plasma. In the plasma, tacrolimus is highly bound to plasma proteins such as albumin and glycoproteins. Partitioning of tacrolimus between erythrocytes and plasma depends on tacrolimus concentration, hematocrit, temperature and plasma protein concentration.
The correlation of tacrolimus concentration with clinical efficacy and toxicity has been studied. 9, 11 Optimal efficacy with minimal toxicity is maintained by careful drug monitoring to assure levels between 10 and 20 g/ml. In order to achieve these levels in the BMT population, tacrolimus is usually given as a continuous infusion beginning 1 day prior to transplant at doses of 0.03 mg/kg/day. Careful monitoring of levels throughout therapy is essential to maintain these levels and levels may fluctuate with medications and with changes in liver and renal function. In particular, certain drugs compete for the same metabolic enzymes and result in decreased tacrolimus metabolism and increased blood levels. These drugs include erythromycin, ketoconazole, fluconazole, diltiazem, verapamil and midazolam. In contrast, other drugs induce the enzyme system, increasing tacrolimus metabolism and decreasing blood levels; these include rifampin, phenobarbital, phenytoin and carbamazepine. Children undergoing BMT receive the same type of prophylaxis against GVHD as adults. Yet the pharmacokinetics of the drug may be different and therefore different doses may be required. Results of pharmacokinetic studies in children undergoing solid organ transplantation suggest that clearance may be greater in some children and therefore that dosing may need to be different. 11 However, these studies have not yet been done in children undergoing BMT.
We therefore retrospectively reviewed the records and data on all of our pediatric patients who underwent BMT over an 18-month period to study tacrolimus clearance.
Materials and methods
This was a retrospective study of all pediatric patients who received tacrolimus as part of their GVHD prophylaxis from December 1996 to June 1998. Data were calculated from information which had been collected for clinically indicated monitoring of tacrolimus. The University of Florida Institutional Review Board approved the retrospective analysis of data of these patients.
Patients
Seven patients underwent BMT using tacrolimus prophylaxis for GVHD from December 1996 to June 1998. Patient characteristics are shown in Table 1 .
GVHD prophylaxis
All patients received our standard tacrolimus-methotrexate regimen which consists of tacrolimus 0.03 mg/kg/day beginning 1 day prior to transplant and continued to day +180. Intravenous continuous infusion was used until the patient engrafted; subsequently, intravenous doses were changed to oral doses in conversion ratios of 4:1 All patients also received methotrexate 5 mg/m 2 on days +1, +3, +6 and +11. Drug levels were obtained on or after the 3rd day, the day at which steady-state concentrations were expected. Doses of tacrolimus were then adjusted as needed to maintain blood level concentrations between 10 and 20 g/ml.
Patients were monitored with drug levels done at least twice weekly, with modifications of dose according to drug level so as to maintain levels between 10 and 20 g/ml.
Patients also had monitoring of liver function and renal function at least twice weekly and more often when clinically indicated. Tacrolimus infusion was stopped at least 15-30 min prior to each blood drawn. Blood was then drawn from a central venous catheter, from a lumen other than that into which the tacrolimus had been given. At least 5 cc of blood was first withdrawn prior to collection of blood sample, this sample was then returned to the patient. Patients were also monitored for clinical outcome including complications such as infection, GVHD, engraftment syndrome, hemorrhage, infection and death.
Tacrolimus assay and measurement of clearance
Tacrolimus assay was performed by microparticle enzyme assay method as previously described. 9 This assay was done by ELISA technique using a kit obtained from Abbott Lab- oratories (Chicago, IL, USA) and using an IMX analyzer. We calculated the plasma clearance by using the infusion rate (Ro) and the plasma concentration at steady state (Cpss) using the following formula: clearance = Ro/Cpss.
Results
Tacrolimus doses and clearance data for all patients are shown in Table 2 . Children had therapeutic doses ranging from 0.03 to 0.04 mg/kg/day in order to achieve adequate blood levels. Initial blood levels ranged from 7.1 to 25.4 ng/ml. After dosage adjustments, repeat blood levels ranged from 10.2 to 17.5 ng/ml. The initial calculated clearance from these therapeutic blood levels at steady state ranged from 79.7 to 142.0 ml/h/kg. The average clearance for the entire course ranged from 60.5 to 153.5 ml/h/kg. In contrast, adults have different tacrolimus pharmacokinetics. The mean terminal elimination half-life of tacrolimus in adults under the same conditions is 18.2 h with total body clearance of 71 ml/h/kg. 4 Clearance changed over time in all patients. Figure 1a g illustrate clearance and plasma concentrations at steadystate peak levels, respectively, in each of the seven patients evaluated in this study. In all but one patient, clearance decreased over the ensuing 2 weeks. One patient (patient No. 1) however had continued increase from 122 to 153.5 ml/h/kg despite changes in doses. This patient was the only one with Schwachman-Diamond syndrome. In all other patients clearance decreased over 2-4 weeks of therapy and the mean decline was 32.5 ml/h/kg.
In two patients there were sharp drops in clearance which were temporally related to liver function tests. In each of the patients, bilirubin and liver enzymes increased. In one of these patients (EJ), liver enzymes became markedly abnormal, whereas increases in bilirubin were mild and transient. In this patient, abnormal liver function tests were considered to be secondary to veno-occlusive disease as evidenced by clinical, ultrasound and CT scan evaluations. She also had evidence of GVHD which may have contributed to the hepatic abnormalities. She was treated with fluid restriction, diuretics, and steroids for her GVHD and liver enzymes normalized within 1 week. In the other patient (NS), bilirubin was markedly abnormal, whereas liver enzymes were only mildly elevated. In this patient, abnormal liver function was related to his grade IV GVHD. He was treated with steroids and the abnormal liver functions also gradually abated. This patient had had prior liver toxicity with hepatomas after prior androgen therapy for his Fanconi's anemia. These hepatomas had completely resolved, and his liver function had returned to normal prior to the transplant. The relationship of clearance of tacrolimus to outcome is shown in Figure 2 . Three of the four patients with the highest clearance levels died. Of these four patients the only one who survived was the one with very high clearance (142 ml/h/kg); this patient had clearance which decreased over the subsequent days with clearance leveling at 91 ml/h/kg at the time of changing from intravenous to oral medication. Nevertheless, he had therapeutic tacrolimus levels. In the three other patients with the highest clearances, all died due to progressive acute GVHD. All of these patients were refractory to steroids, antithymocyte globulin, cellcept and other immunosuppressants used to control GVHD. In contrast, none of the patients with the four lowest clearance developed severe GVHD.
Discussion
This is the first study to show that clearance of tacrolimus is higher in children undergoing BMT compared to adults. Although statistical analysis for differences between children and adults was not possible in this study, the ranges and averages are different, with three of the seven patients having levels outside of the range of any of the adult patients previously reported. One patient had Schwachman-Diamond syndrome and the role of intestinal malabsorption therefore needs to be considered as a possible cause for high clearance and low levels. This, however, was not the case in this patient. First, the tacrolimus was given by the intravenous route in all patients. Second, this patient was on pancreatic supplements and had no clinical evidence of malabsorption. In addition to the high clearance in children, this review suggests that standard adult dose of 0.03 mg/kg/day may not be a sufficient starting dose for children. In this study, children required an average dose of 0.035 mg/kg/day to achieve levels of 10-20 ng/ml. Thus, children seem to require higher doses and need to begin earlier in the transplant course than do adults who receive tacrolimus for prophylaxis against GVHD. Previous studies have shown that children undergoing liver transplantation similarly have increased drug clearance compared to adults undergoing the same procedure.
11
In our study, three of the four patients who had high clearances failed to reach therapeutic levels by the first steady-state assay and required subsequent dosing increase. All but one of the patients who failed to reach therapeutic levels early died of severe and refractory GVHD, even if they achieved adequate levels subsequently.
Finally this study also highlights the need for prospective pediatric pharmacokinetic studies of all medications used in BMT. Assumptions of drug dosing and monitoring based on adult studies may be false and may result in poor clinical outcome. This study has several important limitations. These include the retrospective nature of the analysis, the lack of complete pharmacokinetics, and the lack of very young children or infants in the study population. However, it does suggest the need for further work in this area.
